The diagnosis and risk stratification of MM depends on traditional biomarkers, including M-protein, ß2-microglobulin, albumin, serum free-light chain (SFLC), lactate dehydrogenase (LDH), imaging techniques and cytogenetic abnormalities. This evidence concerns the gene MYOM2 and Miyoshi myopathy.